Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Strupp, M.
Right arrow Articles by Brandt, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Strupp, M.
Right arrow Articles by Brandt, T.
Related Collections
Right arrow Gait disorders/ataxia
Right arrow All Clinical trials
Right arrow Clinical trials Observational study (Cohort, Case control)
Right arrow Ion channel gene defects
NEUROLOGY 2004;62:1623-1625
© 2004 American Academy of Neurology
Brief Communications

Treatment of episodic ataxia type 2 with the potassium channel blocker 4-aminopyridine

M. Strupp, MD, R. Kalla, MD, M. Dichgans, MD, T. Freilinger, MD, S. Glasauer, PhD and T. Brandt, MD FRCP

From the Department of Neurology, University of Munich, Germany.

Address correspondence and reprint requests to Dr. M. Strupp, Department of Neurology, University of Munich, Klinikum Grosshadern, Marchioninistrasse 15, 81377 Munich, Germany; e-mail: mstrupp{at}nefo.med.uni-muenchen.de

Patients with episodic ataxia type 2 (EA2) can often be successfully treated with acetazolamide. The authors report three patients with EA2 (two with proven mutations in the CACNA1A gene) whose attacks were prevented with the potassium channel blocker 4-aminopyridine (4-AP; 5 mg tid). Attacks recurred after treatment was stopped; subsequent treatment alleviated the symptoms (mean follow-up time 6 months). These effects might be due to an improvement of the impaired functioning of Purkinje cells.

Received October 20, 2003. Accepted in final form February 23, 2004.




This article has been cited by other articles:


Home page
 Therapeutic Advances in Neurological DisordersHome page
M. Strupp and T. Brandt
Review: Current treatment of vestibular, ocular motor disorders and nystagmus
Therapeutic Advances in Neurological Disorders, July 1, 2009; 2(4): 223 - 239.
[Abstract] [PDF]

Home page
 BrainHome page
J.C. Jen, T.D. Graves, E.J. Hess, M.G. Hanna, R.C. Griggs, R.W. Baloh, and the CINCH investigators
Primary episodic ataxias: diagnosis, pathogenesis and treatment
Brain, October 1, 2007; 130(10): 2484 - 2493.
[Abstract] [Full Text] [PDF]

Home page
 BrainHome page
R. Kalla, S. Glasauer, U. Buttner, T. Brandt, and M. Strupp
4-Aminopyridine restores vertical and horizontal neural integrator function in downbeat nystagmus
Brain, September 1, 2007; 130(9): 2441 - 2451.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurol. Neurosurg. PsychiatryHome page
J.-M. Kim, W.-S. Ryu, Y.-H. Hwang, and J. S. Kim
Aggravation of ataxia due to acetazolamide induced hyperammonaemia in episodic ataxia
J. Neurol. Neurosurg. Psychiatry, July 1, 2007; 78(7): 771 - 772.
[Full Text] [PDF]

Home page
 J. Neurophysiol.Home page
M. Martina, A. E. Metz, and B. P. Bean
Voltage-Dependent Potassium Currents During Fast Spikes of Rat Cerebellar Purkinje Neurons: Inhibition by BDS-I Toxin
J Neurophysiol, January 1, 2007; 97(1): 563 - 571.
[Abstract] [Full Text] [PDF]

Home page
 BrainHome page
S. Ramat, R. J. Leigh, D. S. Zee, and L. M. Optican
What clinical disorders tell us about the neural control of saccadic eye movements
Brain, January 1, 2007; 130(1): 10 - 35.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
L. H. Eunson, T. D. Graves, and M. G. Hanna
New calcium channel mutations predict aberrant RNA splicing in episodic ataxia
Neurology, July 26, 2005; 65(2): 308 - 310.
[Abstract] [Full Text] [PDF]

Home page
 BrainHome page
M. Strupp, R. Kalla, T. Freilinger, M. Dichgans, and T. Brandt
Dysfunction of the brain calcium channel CaV2.1 in absence epilepsy and episodic ataxia--a comment
Brain, June 1, 2005; 128(6): E32 - E32.
[Full Text] [PDF]

Home page
 BrainHome page
M. G. Hanna, T. D. Graves, S. Jaffe, P. Imbrici, D. M. Kullmann, and on behalf of the authors
Dysfunction of the brain calcium channel CaV2.1 in absence epilepsy and episodic ataxia--authors' response
Brain, June 1, 2005; 128(6): E33 - E33.
[Full Text] [PDF]

Home page
 J. Neurosci.Home page
C. J. C. Weisz, R. S. Raike, L. E. Soria-Jasso, and E. J. Hess
Potassium Channel Blockers Inhibit the Triggers of Attacks in the Calcium Channel Mouse Mutant tottering
J. Neurosci., April 20, 2005; 25(16): 4141 - 4145.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
G. M. Halmagyi and R. J. Leigh
Upbeat about downbeat nystagmus
Neurology, August 24, 2004; 63(4): 606 - 607.
[Full Text] [PDF]

Home page
 NeurologyHome page
July 27 Highlight and Commentary
Neurology, July 27, 2004; 63(2): 197 - 197.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by AAN Enterprises, Inc.